Skip to Content

'
Luis E. Fayad

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX
Clinical Medical Director, Department of Lymphoma/Myeloma, Division of Cancer Medicine, U T M.D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Staff Physician, Lyndon B. Johnson Hospital, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd Unit 429
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2018
Phone: 713-792-2860
Fax: 713-794-5656
Email: lefayad@mdanderson.org

Education & Training

Degree-Granting Education

1985 Catholic University of Guayaquil, Guayaquil, Ecuador, MD, Medicine

Postgraduate Training

7/1994-6/1997 Medical Oncology Fellowship, Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX
7/1993-6/1994 Hematology Fellowship, Hematology, University of Texas Health Science Center, Houston, TX
7/1990-6/1993 Internal Medicine Program, Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, FL

Board Certifications

1/1998 American Board of Internal Medicine Hematology sub
1/1997 American Board of Internal Medicine Medical Oncolo
1/1993 American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/2000-9/2006
Assistant Professor, University of Nevada School of Medicine, Las Vegas, NV, 1/1998-1/2000
Hematology Oncologist, Nevada Cancer Center, Las Vegas, NV, 1/1997-1/2000

Other Appointments/Responsibilities

Staff Physician, Lyndon B. Johnson Hospital, Houston, TX, 9/2002-present

Institutional Committee Activities

Member, CME Advisory Committee, 2008-present
Alternative Member, Medical Records Committee, 2005-present
Medical Liaison, Pharmacy Assistant Program, 2005-present
Member, CRC (Clinical Research Committee), 9/2003-2006
Member, CCAG (Clinical Computing Advisory Group) Committee, 1/2002-present
Member, Pharmacy and Therapeutics Committee, 1/2001-present
Member, IRB, 1/1999-present
Member, Institutional Review Board for Columbia Sunrise Hospital, 1/1999-1/2000
Member, Q & A of CCOP, 1/1998-present
Member, European Society of Medical Oncology, 1/1998-present
Member, Nevada State Medical Association, 1/1998-present
Member, CCOP, 1/1998-present
Member, American Society of Hematology, 1/1997-present
Member, American Society of Oncology, 1/1997-present
Member, American Society of Internal Medicine, 1997-present
Member, American Society of Bone Marrow Transplantation, 1997-present
Member, Texas Medical Association, 1/1996-present
Member, American College of Physicians, 1/1994-present

Honors and Awards

2005 Mentor Award 2005, M. D. Anderson Alumni and Faculty Association

Professional Memberships

NCCN Hon Hodgkin's Lymphoma Panel
Member, 2005-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu S, Banay R, Fayad L, Saville NW, Kwak L. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lympnhoma. Annals of Oncology. In Press.
2. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ, Vega F. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma. Mod Pathol. e-Pub 7/2009. PMID: 19593328.
3. Morschhauser F, Leonard JP, Fayad LE, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer M, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 27(20). e-Pub 5/2009. PMID: 19451441.
4. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang M. 10-year follow-up after intense chemo-immunotherapy with R-HyperCVAD alternating with R-MA and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma, 2009.
5. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-hyperCVAD / methotrexate and cytarabine for untreated aggressive mantle cell lymphoma, 2009.
6. Advani A, Coiffier B, Czuczman M, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf I, Schuler M, Sierra J, Smith M, Verhoef G, Winter J, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of a novel immunoconjugate inotuzumab ozogamicin (CMC-544) for the treatment of b-cell non-hodgkin's lymphoma: results of a phase I study, 2009.
7. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 11/2008. PMID: 18973182.
8. Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 112(6):2583; author reply 2583-4, 9/2008. PMID: 18779406.
9. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143(3). e-Pub 9/2008. PMID: 18764869.
10. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12). e-Pub 4/2008. PMID: 18411419.
11. Zelenter AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacase AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 6(4):356-421, 4/2008. PMID: 18433606.
12. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 112(4):553-559, 3/2008. e-Pub 12/2007. PMID: 18083690.
13. Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Veno NT; Hosing C; Khouri IF; Couril D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. Haematologica 93(2):257-264, 2/2008. e-Pub 1/2008. PMID: 18223284.
14. Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-836, 2/2008. PMID: 18085611.
15. Provencio M, Fayad LE. [High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma]. Med Clin (Barc) 130(2):60-5, 1/2008. PMID: 18221676.
16. Friedberg JW, Williams ME, van der Jagt RH, Forero-Torres A, LaCasce AS, Fayad LE, Bessudo A, Camacho ES, Oliver JW, Chen L, Cohen P, Cheson BD, Robinson KS. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204-210, 1/2008. PMID: 18182663.
17. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2:S57-62, 12/2007. PMID: 18284717.
18. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B.. Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature. Am J Hematol 82(8)(8):725-8, 8/2007. PMID: 17373675.
19. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B.. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 138(4)(4):502-505, 8/2007. e-Pub 6/29/2007. PMID: 17608763.
20. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-9, 6/15/2007. PMID: 17497648.
21. Iwuanyanwu E, Medeiros J, Romaguera JE, Fayad L.. Mantle Cell Lymphoma with a Rare Involvement of the Testicle. Leuk Lymphoma 48(6)(6):1242-3, 6/2007. PMID: 17577795.
22. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma. Cancer 109(12):2481-9, 6/2007.
23. Fayad L, Hagemeister F. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed. Leuk Lymphoma 48(4):657-8, 4/2007. PMID: 17454622.
24. Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109(5):2174-82, 3/2007. e-Pub 11/7/2006. PMCID: PMC1801039.
25. Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 48(2):374-80, 2/2007. PMID: 17325899.
26. Chedraui P, Aguirre W, Hidalgo L, Fayad L. Assessing menopausal symptoms among healthy middle aged women with the Menopause Rating Scale. Maturitas, 2/2007. PMID: 17329046.
27. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2/2007. PMID: 17233846.
28. Herickhoff PK, Keyurapan E, Fayad LM, Silberstein CE, McFarland EG. Scapular Stress Fracture in a Professional Baseball Player: A Case Report and Review of the Literature. Am J Sports Med, 2/2007. PMID: 17322129.
29. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 1/1/2007. PMID: 17133412.
30. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastaba PK, Younes A. Experience with heat schock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 1/2007.
31. Hagemeister FB, Fayad L. The FLIPI and the R-FLIPI: Are we finally ready to use them in Clinical Trials? Am J Hem-Onc 6(6):364-368, 2007.
32. Fayad LM, Fishman EK. Computed tomography of musculoskeletal pathology. Orthopedics 29(12):1076-82, 12/2006. PMID: 17190165.
33. Farber A, Fayad L, Johnson T, Cascio B, Shindle M, Neubauer P, Khanna AJ. Magnetic resonance imaging of the shoulder. Current techniques and spectrum of disease. J Bone Joint Surg Am 88 Suppl 4:64-79, 12/2006. PMID: 17142436.
34. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad,, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 11/2006. e-Pub 10/6/2006. PMID: 17054068.
35. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 11/2006. e-Pub 9/27/2006. PMID: 17008093.
36. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-302, 9/2006. PMID: 16902984.
37. Rosen RS, Fayad L, Wahl RL. Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT. J Nucl Med 47(8):1274-80, 8/2006. PMID: 16883005.
38. Keyurapan E, Hu SJ, Streiff MB, Fayad LM, McFarland EG. Iatrogenic symptomatic chest wall hematoma after shoulder arthroplasty. A report of two cases. J Bone Joint Surg Am 88:1603-8, 7/2006. PMID: 16818988.
39. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-9, 4/2006. PMID: 16575009.
40. Fayad L, Younes A. Novel treatment strategies for aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 7(6):733-48, 4/2006. PMID: 16556089.
41. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(3):258-310, 3/2006. PMID: 16507273.
42. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-5, 3/2006. PMID: 16396772.
43. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107(4):1731-2, 2/2006. PMID: 16461762.
44. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-23, 10/2005. e-Pub 9/6/2005. PMID: 16145068.
45. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-51, 5/2005. PMID: 15806128.
46. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-7, 4/2005. PMID: 15800314.
47. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2/2005. e-Pub 12/21/2004. PMID: 15613697.
48. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 10/2004. e-Pub 9/7/2004. PMID: 15353540.
49. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Non-ablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-12, 12/2003. PMID: 14645431.
50. Ha CS, Kong JS, McLaughlin P, Tucker SL, Fayad LE, Hess MA, Wilder RB, Cabanillas F, Cox JD. Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 57(3):748-54, 11/2003. PMID: 14529780.
51. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-8, Sep-Oct, 9/2003. PMID: 12883733.
52. Goy A, Ramdas L, Remache YK, Gu J, Fayad L, Hayes KJ, Coombes KR, Barkoh BA, Katz R, Ford R, Cabanillas F, Gilles F. Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations. Lab Invest 83(6):913-6, 6/2003. PMID: 12808126.
53. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14(5):737-44, 5/2003. PMID: 12702528.
54. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-91, 2/2003. PMID: 12548600.
55. Fayad L. Durable Local responses with Subtherapeutic doses of concurrent Radiation and Gemcitabine in a patient with refractory Hodgkin’s disease: Review of Halepota et al case. Clin Adv in Hematol & Oncol. 1(7):416, 2003.
56. Fayad L, Pro B, Romaguera JE. Mantle cell lymphoma: A review. Hematología, Citocinas, Y Terapia Celular 2:100-112, 2003.
57. Anas Younes, Luis Fayad, Barbara Pro, Peter McLaughlin, Frederick Hagemeister, Paul Mansfield, Gary Clayman, LJeffrey Medeiros, John Manning, Jonathan Lewis, Pramod Srivastava. Safety and Efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) Vaccine Therapy in Patients with Relapsed or Previously Untreated Low-Grade Non-Hodgkin Lymphoma. Blood 102(11):898a, 2003.
58. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97(1):256-63, 2001. PMID: 11133769.
Other Articles
1. Provencio M; Fayad LE. High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma. Medicina clinica 130(2):60-65, 1/2008.

Abstracts
1. Fowler N, McLaughlin P, Kwak LW, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 27(15S):445, 5/2009.
2. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister F. Differential JAK-STAT pathway activation in primary mediastinal large B-cell lymphoma produces distinct patterns of cytokine pathway response and predicted sensitivity to small molecule inhibitors, 2009.
3. Fanale MA, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. A phase I study of bortezomib in combination with ice (bice) in patient with relapsed/refractory classical hodgkin lymphoma. Blood 112(3048), 11/2008.
4. Kurzrock R, Fayad LE, Voorhees P, Furman RR, Lonial S, Borghaei H, Jagannath S, Sokol L, Cornfeld M, Qi M, Jiao T, Herring J, Qin X, van Rhee F,. A phase I study of CNTO 328, an anti-interleukin-6 monoclonal antibody in patients with B-cell non-hodgkin's lymphoma, multiple myeloma, or castleman's disease. Blood 112(1009), 11/2008.
5. Cataldo VD, Thompson MA, Toth BB, Sanjorjo P, Bekele BN, Jimenez C, Murphy WA, Huen AO, Arbuckle RB, Fanale M, Fayad LE, Fowler N, Kwak LW, McLaughlin PW, Neelapu SS, Pro B, Rodriguez AM, Shah J, Hagemeister FB. Bone loss in patients with previously untreated lymphoma: the effect of periodontal disease on the use of zoledronic acid. Blood 112(5297), 11/2008.
6. Van Rhee F, Fayad LE, Voorhees P, Furman RR, Borghaei H, Lonial S, Sokol L, Crawford J, Cornfeld M, Qi M, Herring J, Qin X, Kurzrock R. CNTO 328, a monoclonal antibody to interleukin-6, is active as a study agent in Castleman's disease: preliminary results of a phase I study. Blood 112(1008), 11/2008.
7. Wang M, Zhang L, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera JE. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112(3058), 11/2008.
8. Thomas DA, Kantarjian HM, Cortes J, Faderl S, Wierda WG, Ravandi F, Rodriguez MA, Fayad LE, O'Brien S. Long-term outcome after hyper-CVAD and rituximab chemoimmunotherapy for burkitt (BL) or burkitt-like (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (ALL). Blood 112(1929), 11/2008.
9. Mazloom A, Reed VK, Cabanillas F, Fayad LE, Pro B, Iyengar P, McLaughlin P, Urbauer DL, Dabaja BS. Marginal zone lymphoma: factors that affect the final outcome, a study of 275 patients. Blood 112(3764), 11/2008.
10. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Neelapu S, Rodriguez MA, Fayad LE, Younes A, Kwak L. Pentostatin, cyclophosphamide, and rituximab (PCR) achieve high response rates in indolent B-cell lymphoma without prolonged myelosuppression. Blood 112(835), 11/2008.
11. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak L, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trail of bortezomib in combination with rituximab-hyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. Blood 112(3051), 11/2008.
12. Garg RJ, Wierda W, Fayad LE, Estrov Z, Bickel SM, O'Brien, S. Phase II study of dasatinib in patients with relapsed CLL. Blood 112(4197), 11/2008.
13. Romaguera JE, Fayad LE, Rodriguez AM, Hagemeister FB, Pro B, McLaughlin PW, Younes A, Samaniego F, Shah J, Weaver P, Hartig K, Cabanillas F, Kwak L, Kantarjian H, Wang M. Rituximab (R) + hypercvad alternating with r-methotrexate/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). Blood 112(833), 11/2008.
14. Fayad LE, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, Coiffier B, Hess G, Gine E, Advani Anjali, Offner F, Vandendries ER, Shapiro M, Dang NH. Safety and clinical activity of the anit-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymhoma: preliminary report of a phase 1/2 study. Blood 112(266), 11/2008.
15. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korblin M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogenic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 6/2008.
16. Rodriguez MA, Fanale M, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad LE, Durand J. Acitivity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study. J Clin Oncol 26(15S):725s (#20505), 5/2008.
17. Cultrera JL, Nunez RF, Romaguera JE, Hagemeister FB, Rodriguez MA, Fayad LE, Pro B. Early Fluro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin's lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C). J Clin Oncol 26(15S):463s (#8538), 5/2008.
18. Zhou X, Huen A, Teegala S, Ji S, Fayad LE, Hagemeister FB, Vadhan-Raj S. Incidence and significant predicting factors for chemotherapy-induced severe thrombocytopenia in lymphoma patients. J Clin Oncol 26(15S):726s (#20519), 5/2008.
19. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad LE, Colffier B, Morchhauser F. Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. J Clin Oncol 26(15S):142s (#3043), 5/2008.
20. Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, fENG l, Younes A. Long-term follow-up of pacitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(15S):478s (#8599), 5/2008.
21. Shah N, Cabanillas F, Feng L, McIntyre B, McLaughlin P, Rodriguez MA, Romaguera JE, Younes A, Hagemeister FB, Kwak L, Fayad LE. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. J Clin Oncol 26(15S):475s (#8589), 5/2008.
22. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad L, Colffier B, Moschhauser F. Acitivity of Veltuzumab, a Second-Generation Humanized Anti-CD20 MAB, in Laboratory and Clinical Studies. Annals of Oncology 19(4):iv130 (#144), 2008.
23. Berkova Z, Maeng H, Wang S, Wang S, Wise J, Hawke D, Campbell M, Fayad L, Kwak L, Samaniego F. CD74 Associates with FAS and Inhibits FAS-Mediated Apoptotic Signaling. Annals of Oncology 19(4):iv169 (#287), 2008.
24. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide in Combination with Rituximab is Effective with Manageable Toxicity in a Phase I/II study in Relapsed/Refractory Mantle Cell Lymphoma. Annals of Oncology 19(4):iv174 (#306), 2008.
25. Samaniego F, Fanale M, Pro B, Hagemeister F, McLaughlin P, Romaguera J, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin Combined with Cyclophophamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lymphoma. Annals of Oncology 19(4):iv182 (#334), 2008.
26. Romaguera JE, Pro B, Fayad L, McLaughlin P, Wang M, Weaver P, Hartig K, Hagemeister F, Rodriguez MA, Younes A, Samaniego F, Fanale M, Kwak L, Feldman T, Goy A. Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. Annals of Oncology 19(4):iv214 (#444), 2008.
27. Hamlin PA, Moskowitz CH, Wegner B, Noy A, Gerecitano J, Palomba ML, Portlock C, Straus D, Pro B, Fayad L, Rodriguez A, Zelenetz AD. Sequential RCHOP and YTTRIUM-90 Ibritumomab Tiuxetan (RIT) is a highly effective regimen for High Risk Elderly Patients with Untreated DLBCL. Annals of Oncology 19(4):iv100 (#054), 2008.
28. Xiao Zhou, Auris Huen, Shyam Teegala, Yuan Ji, Luis Fayad, F.B. Hagemeister, and Saroj Vadhan-Raj. Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors. Blood 110(11):66B, 11/2007.
29. Anas Younes, Barbara Pro, Michelle Fanale, Peter McLaughlin, Sattva Neelapu, Luis Fayad, Amanda Wedgwood, Daniela Buglio, Tracy Patterson, Marja Dubay, Zuomei Li, Robert E. Martell, M. Renee Ward, and R. Gregory Bociek. Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). Blood 110(11):756a, 11/2007.
30. Michael Wang, Luis Fayad, Frederick Hagemeister, Sattva Neelapu, Barry Samuels, Felipe Samanigo, Barbara Pro, Qing Yi, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, Jerry Zeldis, Larry Kwak, and Jorge Romaguera. Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood 110(11):755a, 11/2007.
31. Deborah A. Thomas, Hagop Kantarjian, Jorge Cortes, Stefan Faderl, Farhad Ravandi-Kashani, William Wierda, Alma Rodriguez, Luis Fayad, and Susan O’Brien. Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL). Blood 110, 11/2007.
32. Constantine S. Tam, Celina Ledesma, Martin Korbling, Luis E. Fayad, Michael Wang, Amin Alousi, Chitra Hosing, Partow Kebriaei, Gabriela Rondon, Sergio A. Giralt, Paolo Anderlini, Uday Popat, Daniel Couriel, Barbara Pro, Barry Samuels, Frederick Hagemeister, Richard E. Champlin, and Issa F. Khouri. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. Blood 110(11):149a, 11/2007.
33. Issa F. Khouri, Rima M. Saliba, Martin Korbling, Chitra Hosing, Luis Fayad, Ming S. Lee, Felipe Samaniego, Barry I. Samuels, Daniel Couriel, Fredrick Hagemeister, Peter McLaughlin, and Richard E. Champlin. Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up. Blood 110(11):150a, 11/2007.
34. Maria Alma Rodriguez, Michelle Fanale, Fredrick Hagemeister, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Larry Kwak, Luis Fayad, Xuelin Huang, and Jean Bernard Durand. Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL). Blood 110(11):187B, 11/2007.
35. Barbara Pro, Luis Fayad, Jorge Romaguera, Michelle Fanale, Anas Younes, Fredrick B. Hagemeister, Felipe Samaniego, Peter McLaughlin, M.A. Rodriguez, Larry Kwak, and Nam H. Dang. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood 110(11):1013A, 11/2007.
36. Luis Fayad, Barbara Pro, Fredrick Hagemeister, Fernando Cabanillas, Felipe Samaniego, Peter McLaughlin, Michael Wang, Sattva Neelapu, Larry Kwak, Jorge Romaguera, and Maria A. Rodriguez. R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years. Blood 110, 11/2007.
37. Amanda R. Wedgwood, Michelle A. Fanale, Luis E. Fayad, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Jorge Romaguera, Maria A. Rodriguez, Felipe Samaniego, and Anas Younes. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. Blood 110(11):71a, 11/2007.
38. Fanale M, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma. Blood 110(11):198B, 11/2007.
39. Michael J. Overman, Lei Feng, Barbara Pro, Peter McLaughlin, Mark Hess, Felipe Samaniego, Anas Younes, Jorge E. Romaguera, Frederick B. Hagemeister, Larry Kwak, Fernando Cabanillas, Maria A. Rodriguez, and Luis E. Fayad. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood 110, 11/2007.
40. Amin M. Alousi, Chitra Hosing, Rima M. Saliba, Rosamar B. Valverde, Farzaneh Maadani, Martin Korbling, Grace J. Okoroji, Luis E. Fayad, Anne M. Stachowiak, William D. Erwin, Paolo Anderlini, Marcos J. de Lima, Sergio A. Giralt, Uday R. Popat, Partow Kebriaei, Naoto T. Ueno, Peter W. McLaughlin, Barbara Pro, Michael Wang, Alma Rodriguez, Fredrick B. Hagemeister, Homer A. Macapinlac, Donald A. Podoloff, Richard E. Champlin, and Issa F. Khouri. Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Blood 110(11):191a, 11/2007.
41. Suizhao Wang, Shu Wang, Hoyoung Maeng, Daniel P. Young, Om Prakash, Luis E. Fayad, Anas Younes, and Felipe Samaniego. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109, 3/2007.
42. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, and Romaguera J. A Phase I/II Study of Lenalidomide (Len) in Combination with Rituximab (R) in Relapsed/Refractory Mantle Cell Lymphoma (MCL) with Early Evidence of Efficacy. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 25(18s):[8030], 2007.
43. Falchook GS, Dhillon N, Moulder S, Duvic M, Ng C, Hong D, Camacho L, Lim J, Wang M, Fayad L, and Kurzrock R. Age-Stratified Phase I Trial of a Combination of Bortezomib, Gemcitabine, and Liposomal Doxorubicin in Patients with Advanced Malignancies. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):14087, 2007.
44. Lenihan DJ, Massey MR, Baysinger K, Steinert D, Fayad L, Yusuf SW, Chiu A, Durand A, and Yeh ET. Early Detection of Cardiotoxicity During Chemotherapy Using Biomarkers. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):19521, 2007.
45. Huen A, Romaguera JE, Fayad LE, Teegala SR, Ji Y, and Vadhan-Raj S. Increased Toxicity Associated with Delayed Clearance of Methothrexate (MTX) in Patients with Lymphoma Receiving High-Dose MTX. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):[19578], 2007.
46. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon M, Coleman M, Horne H, Teoh N, Wegner WA, and Goldenberg DM. Low Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Refractory or Recurrent NHL: Phase I/II Results. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8032, 2007.
47. Rodriguez MA, Temple S, Fayad L, Hagemeister F, McLaughlin P, Romaguera J, and Cabanillas F. Predictive Value for Survival of a Risk Model of Two Serological Markers, Beta-2-Microglobulin (B2M) and Lactic Dehydrogenase (LDH), in Diffuse Large Cell Lymphoma (DLCL). J Clin Oncol 25(18s):10599, 2007.
48. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Kwak L, Romaguera J, and Rodriguez MA. R-HCV AD/R-MTX-ARAC is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features: M.D. Anderson Experience in 40 Patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8058, 2007.
49. Teegala SR, Zhou X, Huen A, Ji Y, Fayad LE, Romaguera JE, and Vadhan-Raj S. Risk Factors for Neutropenic Fever in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Onco 25(18s):19616, 2007.
50. Zhou X, Teegala SR, Huen A, Ji Y, Fayad LE, Romaguera JE, Hagemeister FB, and Vadhan-Raj S. Risk Factors for Severe Anemia Requiring Red Blood Cell Transfusions in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):19537, 2007.
51. Kornblau SM, Jackson CE, Worthing A, Faderl S, Beran M, Fayad L, Ravhandi-Kashani F, Borthakur G, Gale R, Vertovsek S. A phase I trial of a novel organic arsenic S-dimethylarsino-glutathione (ZIO-101). J Clin Oncol 24 (18s):664s, 2006.
52. Pro B, Fayad L, Romaguera J, Hagemeister FB, Samaniego F, McLauhglin P, Rodriguez AM, Kwak L, Walker P, Dang N. A phase II of HCVDDoxil alternated with methotrexate-cytarabine in patients with newly diagnosed T-cell lymphoma. J Clin Oncol 24 (18s):103s, 2006.
53. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu S, Fayad L, Wedgwood A, Dubay M, Backstrom J, and Martell RE. A Phase II Study of a Novel Oral Isotype-Selective Histone Deacetylase(HDAC) Inhibitor in Patients with Relapsed or Refractory Hodgkin Lymphoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8000, 2006.
54. Forero-Torres A, Cohen P, Cheson BD, Robinson KS, La Casce AS, Fayad L, Camacho ES, Williams ME, Van de Jagt RH, Friedberg JW. A phase II study of Bendamustine for rituximab refractory B-cell Non-Hodgkin’s lymphoma. ESMO, 2006.
55. Pro B, Nunez RF, Romaguera J, Rodriguez MA, Hagemeister, F, and Fayad L. Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma. Blood 108(11):[2404], 2006.
56. Fayad L and Cannata J. Adult Langerhans’ Cell Histiocitosis (LCH): A Single Institution Experience. Blood 108(11):[3890], 2006.
57. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang L, Kantarjian HM, Beasley V, Medeiros LJ, Katz RL, and Cabanilla F. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood 108(11):[2749], 2006.
58. Fayad L, Patel H, Verhoef G, Czuczmar M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, and Advani A. Clinical Activity of the immunoconjugate CMC-544 in B-Cell malignancies: Cohort of a Phase I Study. Blood 108(11):[2711], 2006.
59. VanRhee F, Fayad L, Borghaei H, Voorhees PM, Orlowski RZ, Furman RR, Zaki M, Prabhakar U, Jiao T, Lihou C, Garay CA, and Kurzrock R. CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) – Prelimi Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematolog Malignancies. Blood 108(11):[2728], 2006.
60. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji GJ, Stachowiak AM, Samuels BI, Anderlini P, Couriel DR, de Lima M, Giralt S, Popat U, kebriaei P, Ueno N, Qazilbash MH, McLaughlin P, Hagemeister FB, Younes A, Podoloff DA, and Champlin RE. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed and Non-Hodgkin’s Lymphoma (NHL). Blood 108(11):[315], 2006.
61. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, kwak L, and Rodriguez MA. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. 108(11):[2770], 2006.
62. Teegala S, Zhou X, Huen A, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, and Vadhan-Raj S. High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors. Blood 108(11):[4103], 2006.
63. Huen A, Zhou X, Teegala S, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy. Blood 108(11):[3994], 2006.
64. Samaniego F, Fayad L, Pro B, McLaughlin P, Rodriguez MA, Hagemeister FB, Fanale M, Neelapu S, Younes A, and Kwak L. Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma. Blood 108(11):[4722], 2006.
65. Kurzrock R, Voorhees P, Fayad L, Orlowsky R, Van Thee F, Furman R, Borghaei H, Zaki MH, Prabhakar U, Garay C. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in subjects with hematology malignancies. J Clin Oncol 24(18s):664s, 2006.
66. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera J, and Stromatt S. Results of a Phase I/II Trial of Pixantrone in combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed Refractory Indolent Non-Hodkin’s Lymphoma (NHL). Blood 108(11):[2758], 2006.
67. Younes A, Fayad L, Goy A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros LJ, Wedgwood A, and Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108(11):[2742], 2006.
68. Kadia T, Fayad L, Rodriguez MA, McLaughlin P, and Pro B. Retrospective Review of Angiommunoblastic T-Cell Lymphoma: The MD Anderson Cancer Experience. Blood 108(11):[4690], 2006.
69. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Schuster S, Dyer MJS, Petillon MO, Coleman M, Bahkti A, Horen H, Xu L, Teoh N, Wegener W, and Goldenberg DM. Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. Blood 108(11):[2719], 2006.
70. Faderl S, Ferrajoli A, Wierda WG, O’Brien S, Ravandi-Kashani F, Fayad L, Thomas D, Kantarjian H, Browning ML, and Keating MJ. The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL). 108(11):[2827], 2006.
71. Younes A, Pro B, Fayad L, Dang N, Romaguera J. (Velcade) for the treatment of relapsed classical Hodgkin’s lymphoma. Ann Oncol 16(Suppl 5):v210 (#593), 2005.
72. Fayad L, Liebman J, Mediano M, Cohen G, Pro B, Romaguera J, Countouridis A, Lymboura M, Comis S, Laffranchi B. A phase I/II trial of pixantrone combined with fludarabine (FL), dexamethasone (DEX) and rituximab (FPD-R) for treatment of recurrent indolent B-cell non-Hodgkin’s lymphomas. . Ann Oncol 16(Suppl 5):v156 (#403), 2005.
73. Pro B, Leber B, Smith MR, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. A Phase II Trial of Oblimersen Sodium (G3139) plus Rituximab for Treatment of Patients with Recurrent B-cell Non-Hodgkin’s Lymphoma. . Ann Oncol 16(Suppl 5):v68 (#103), 2005.
74. Younes A, Fayad L, Romaguera JE, Pro B, and Wang M. ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study. Blood 106(11):[4790], 2005.
75. Khouri IF, Saliba RM, Hosing CM, Acholonu SA, Fayad LE, Korbling MJ, Saenz C, Pro B, Samuels BI, de Lima MJ, Giralt SA, Younes A, McLaughlin P, and Champlin RE. Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL). Blood 106(11):[48] 19a, 2005.
76. Friedberg JW, Cohen P, Cheson BD, Robinson KS, Forero-Torres A, Fayad L, La Casce AL, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver J, and Benaim E. Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01). Blood 106(11):[229] 70a, 2005.
77. Soriano AO, Thompson M, Romaguera J, Rodriguez MA, Hagemeister FB, Fayad L, Admirand JH, and Pro B. Follicular Dendritic Cell Sarcoma (FDCS): A Rare and Incurable Disease. Blood 106(11):[3892], 2005.
78. Younes A, Fayad L, Pro B, Goy A, Romaguera JE, Hagemeister FB, and McLaughlin P. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. Blood 106(11):[1498] 431a, 2005.
79. Romaguera JE, Fayad LE, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu S, Goy AH, Beasley V, and Kwak L. High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A). Blood 106(11):[2446] 688a, 2005.
80. Romaguera J, Fayad L, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, MedeirosJ, Katz,R, Gagneja H, Samuels B, Cabanillas F. High rates of Failure-Free Survival (FFS) and Overall Survival (OS) in untreated Mantle Cell lymphoma(MCL) after Rituximab plus HyperCVAD (R-HCVAD) alternating with rituximab plus High-Dose Methotrexate-Cytarabine (R-M/A). . Ann Oncol 16(Suppl 5):v95 (#197), 2005.
81. Pro B, Cabanillas F, Fayad L. High-serum b2 microglobulin is an important independent prognostic factor for disease progression in patients with follicular lymphoma. . Ann Oncol 16(Suppl 5):v149 (#381), 2005.
82. Fayad L, Dang J, Keating M. Hodgkin’s disease variant of Richter’s syndrome, an update of the M. D. Anderson experience. . Ann Oncol 16(Suppl 5):v114 (#262), 2005.
83. Dang NH, McLaughlin P, Fayad L, Romaguera J, Hagemeister F, Younes A, Neelapu S, Samaniego F, Jones D, Walker PL, Rodriguez MA, Kwak L, and Pro B. Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma. Blood 106(11):[3349] 936a, 2005.
84. Khouri IF, Saliba RM, Lee MS, Okoroji GJ, Fayad L, Maadani F, Hosing C, Samuels B, Giralt S, de Lima M, Pro B, Younes A, McLaughlin P, Kwak L, and Champlin RE. Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. Blood 106(11):[44] 19a, 2005.
85. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, dang N, Samaniego F, Rodriguez M, Fayad L. Paclitaxel plus Topotecan plus Rituximab (TTR): An Effective Salvage Program for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma (NHL). Ann Oncol 16(Suppl 5):v101 (#220), 2005.
86. Dang NH, Pro B, Hagemeister F, Samaniego F, Jones D, Rodriguez M, Goy A, Romaguera J, Walker PL, Younes A, Neelapu S, Kwak L, and Fayad L. Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood 106(11):[3350] 936a, 2005.
87. Pro B, Smith MR, Leber B, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. Phase II study of Oblimersen Sodium and Rituximab in Patients with Recurrent B-cell Non-Hodgkin’s Lymphoma. J Clin Oncol 23(16S):587S (#6611), 2005.
88. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Younes A, and Cabanillas F. Phase II Study of Sphingosomal Vincristine in CHOP+/ – Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients. Blood 106(11):[943] 277a, 2005.
89. Jabbour E, Hosing C, Pro B, Khouri I, Fayad L. Positive Pre-transplant PET/Ga67 (Ga) predicts poor outcome in refractory and relapse Hodgkin’s lymphoma. Ann Oncol 16(Suppl 5):v121 (#285), 2005.
90. Jabbour E, Hosing C, Pro B, Champlin R, Khouri I, Romaguera J, Fayad LE. Pre transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma (HL). Proceedings ASCO. J Clin Oncol 23(16S):562S (#6509), 2005.
91. Fayad L, Romaguera J, hart S, Younes A, Pro B, Hagemeister F, McLaughlin P, Dang N, Pretti A, Sarris A, Gil F. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. J Clin Oncol 23(16S):591S (#6624), 2005.
92. Thompson MA, Pro B, Sarris A, Hagemeister FB, Goy A, Bleyer A, Cabanillas F, Samaniego F, and Fayad LE. Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma. Blood 106(11):[2681] 753a, 2005.
93. Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Dang N, Goy A, Romaguera J, Pro B, Beasley V, Cabanillas F, and Rodriguez M. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL). Blood 106(11):[941] 277a, 2005.
94. Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, Romaguera J, Rodriguez M, Samaniego F, Dang N, et al. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin’s lymphoma: A novel combination program targeting the cancer cells and the reactive B-cells in the microenviroment. . Ann Oncol 16(Suppl 5):v196 (#545), 2005.
95. McLaughlin P, Liu NS, Grimmm E, Fayad L, Hagemeister FB, Nunez G, Romaguera J, Goy A, Samaniego F, Wang M, Ayala A, Lee BN, Reuben JM, Kwak L, Rodriguez MA. Rituximab plus GM-CSF (Leukineä) for Indolent Lymphoma. Ann Oncol 16(Suppl 5):v68 (#104), 2005.
96. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Safety and efficacy of single fixed dose pegfilgrastin (Neulasta) in chemotherapy regimens given every 14 days: Results of ABVD plus pegfilgrastin in patients with Hodgkin’s lymphoma. . Ann Oncol 16(Suppl 5):v196 (#546), 2005.
97. Younes A, McLaughlin P, Fayad LE, Goy A, Romaguera JE, Pro B, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, and Medeiros J. Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab. Blood 106(11):[1499] 431a, 2005.
98. McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, Dang N, Goy A, Samaniego F, Hess M, Lee M, Medeiros J, Fayad L, Pro B, Jiang Y, Ayala A, Cabanillas F. Stage IV indolent Lymphoma: A randomized trial of concurrent vs. sequential FND (fludarabine, mitoxantrone, dexamethasone) and rituximab with interferon maintenance. Ann Oncol 16(Suppl 5):v109 (#247), 2005.
99. Cohen P, Cheson B, Friedberg J, Robinson KS, Foran J, Fayad L, Tulpule A, Bessudo A, van der Jagt R, Suster MS, Multani PS. The novel alkylator Bendamustine HCL is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity. . J Clin Oncol 23(16S):576S (#6564), 2005.
100. Georgakis G, Li Y, Rassidakis G, Fayad L, Medeiros L, Younes A. Therapeutic inhibition of heat schock protein-90 function in Hodgkin’s lymphoma. Ann Oncol 16(Suppl 5):v215 (#6074), 2005.
101. Fayad L, Pro B, Liu Q, Hess M, Hagemeister F, Romaguera J, Samaniego F, Cabanillas F, Rodriguez A, Younes A, Wang M, and McLaughlin P. Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL). Blood 106(11):[933] 274a, 2005.
102. Tsimberidou AM, O’Brien S, Kantarjian H, Koller C, Hagemeister F, Fayad L, Lerner S, and Keating MJ. Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience. Blood 106(11):[976] 287a, 2005.
103. Khouri I, Saliba R, Lee M, Okoroji GJ, Fayad L, Acholonu S, Maadani F, Hosing C,Younes A, McLauhglin P, Champlin R. Transplant Lite with rituximab-containing conditioning regimens for Non-Hodgkin’s Lymphomas (NHL): An Update. Ann Oncol 16(Suppl 5):v101 (#218), 2005.
104. Camboni G, Fayad L, Tulpule A, Modiano M, Espina BM, Cabanillas F, Levine AM. A phase I/II of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL). J Clin Oncol 23:578 (#6590), 2004.
105. Dang NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodruiguez MA, Goy A, Romaguera JE, Walker P, Kwak L, Fayad L. Interim Analysis of a Phase II study of Dinileukin Diftitox (ONTAK) for relapsed/refractory T-cell Non-Hodgkin’s lymphoma. . Blood 104(11):722a (#2641), 2004.
106. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Long-term safety and efficacy of single administration of a fixed dose peffilgrastin (Neulasta) in inducing neutrophil count recovery after ABVD chemotherapy in patients with Hodgkin’s lymphoma. . Blood 104(11):245b (#4646), 2004.
107. Fayad L, Liebmann J, Modiano M, Cohen GI, Pro B, Romaguera J, Davite C, Lymboura M, Comis S, Laffranchi B. Preliminary results of a Phase I/II trial of BBR-2778 (pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatments of patients with relapsed/refractory indolent non-Hodgkin’s lymphoma. Blood 104(11):373a (#1324), 2004.
108. Samaniego F, Wang S, Young D, Fayad L, Wang S. Simian Virus 40 DNA sequences in non-Hodgkin’s lymphoma. J Clin Oncol 23:581 (#6604), 2004.
109. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- rituximab is a promising new treatment for patients with high-risk untreated aggressive non-Hodgkin’s lymphoma (NHL): Follow-up results of a phase II study. Blood 104(11):234b (#4602), 2004.
110. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin’s lymphoma (NHL): Follow-up of a phase II study. . J Clin Oncol 23:745 (#8080), 2004.
111. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase (ph) 2 tudy of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphoma (NHL). . J Clin Oncol 23:575 (#6581), 2004.
112. Nina SLiu, Elizabeth Grimm, Nancy Poindexter, Maria ARodriguez, Fredrick BHagemeister, Barbara Pro, Luis Fayad, Bang NLee, James MReuben, Peter McLaughlin. [1495] Antibody Dependent Cellular Cytotoxicity and Natural Killer Cell Activity in Patients with Recurrent Indolent Lymphoma Receiving Rituximab in Combination with GM-CSF. Blood 102(11):411a (#1495), 2003.
113. Nam HDang, Fredrick BHagemeister, Luis Fayad, Barbara Pro, Peter McLaughlin, Jorge ERomaguera, Felipe Samaniego, Andre Goy, Michael Wang, Pamela LWalker, Barry Samuels, Dan Jones, Maria ARodriguez. Analysis of a Phase II Study of Denileukin Diftitox (ONTAK) for B and T-Cell Non-Hodgkins Lymphoma. Blood 102(11):303b (#4935), 2003.
114. Anas Younes, Barbara Pro, Andre Goy, Luis Fayad, Jorge Romaguera. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Disease. Depletion of Benign B-Cells from HD Microenvironment by Rituximab May Enhance the Activity of Gemcitabine. Blood 102(11):412a (#1500), 2003.
115. Pro B, Smith MR, younes A, Dang NH, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Rodriguez MA, Samuels B, Arredondo Y, Frankel SR, Zwiebel JA. Genasense (BCL-2 Antisense) plus Rituximab is active in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma. . Submitted to ASH 2003, 2003.
116. Issa FKhouri, Rima MSaliba, Sandra Acholonu, Grace-Jula Okoroji, Chitra Hosing, Luis Fayad, Daniel RCouriel, Barbara Pro, Sergio Giralt, Borje Andersson, Anas Younes, Peter McLaughlin, Richard EChamplin. Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stme Cell Transplantation (ASCT) fro Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL): The Impact of Histologies of follicular (FL) Origin. Blood 102(11):735a (#2716), 2003.
117. Levine A, Fayad L, Modiano M, Camboni G, Cabanillas F. Phase I study of BBR-2778 in BSHAP for relapsed aggressive non-Hodgkin's lymphoma. . Exp Hematol 31(Suppl 1):110, 2003.
118. Levine AM, Fayad L, Modiano M, Camboni G, Cabanillas F. Phase I study of Pixantrone in BSHAP for relapsed non-Hodgkin’s Lymphoma. . Proceedings of the International Society of Experimental Hematology, France (#154), 2003.
119. Barbara Pro, Fernando Cabanillas, Nam HDang, Luis EFayad, Andre Goy, Peter McLaughlin, Maria ARodriguez, Jorge Romaguera, Felipe Samaniego, Hillary HWu, Mark Hess, David LGold, Fredrick BHagemeister. Prognostic Factors in Follicular Lymphoma: The Importance of Beta-2 Microglobulin. . Blood 102(11):281b (#4845), 2003.
120. Alexandra MLevine, Luis Fayad, Anil Tulpule, Manuel Modiano, Byron MEspina, Gabriella Camboni, Fernando Cabanillas. Results of a Phase I/II Trial with BBR-2778 (Pixantrone), Methylprednisolone, Cisplatin, and Cytosine Arabinoside (BSHAP) in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma (NHL). Blood 102(11):640a (#2364), 2003.
121. Anas Younes, Peter McLaughlin, Andre Goy, LJeffrey Medeiros, Dan Jones, Luis Fayad, Lynne Abruzzo, Barbara Pro. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease: A Novel Combination Program Targeting the Cancer Cells and the Microenvironment. Blood 102(11):27a (#83), 2003.
122. AYounes, LEFayad, BPro, PMcLaughlin, FBHagemeister, PMansfield, GClayman, LJMedeiros, JLewis, PSrivastava. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low-grade lymphoma. Proceedings of ASCO 22:2294, 2003.
123. Anas Younes, Luis Fayad, Jorge Romaguera, Barbara Pro, Nam Dang, Michael Wang. Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after 170 Consecutive Doses of ABVD Chemotherapy in Patients with Hodgkin Lymphoma: Safety of Pegfilgrastim with q14-Day Chemotherapy Regimens. Blood 102(11):637a (#2352), 2003.
124. Qi Liu, Luis Fayad, Fredrick BHagemeister, MAlma Rodriguez, Anas Younes, Barbara Pro, Srdan Verstovsek, Fernando Cabanillas, Apostolia Tsimberidou, Mark Hess, Ana Ayala, Marilyn Clemons, Peter McLaughlin. Stage IV Indolent Lymphoma: 25 Years of Treatment Progress. Blood 102(11):398a (#1446), 2003.
125. Anas Younes, Peter McLaughlin, Jorge Romaguera, Frederick Hagemeister, Barbara Pro, Nam HDang, Felipe Samaniego, Maria ARodriguez, Luis Fayad. Taxol Plus Topetecan Plus Rituximab (TTR) with G-CSF Support: An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgekin Lymphoma (NHL) Who Failed CHOP-Like and Platinum-Based Therapy. Blood 102(11):142a (#489), 2003.
126. Maria Alma Rodriguez, Andreas Sarris, Kimberly East, Nam HDang, Luis Fayad, Andre Goy Fredrick BHagemeister, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Felipe Samaniego, Anas Younes, Fernando Cabanillas. A Phase II study of Liposomal Vincristine in CHOP with Rituximab for Patients with Untreated Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL): A Safe and Effective Combination. Blood 100:338, 2002.
127. Anas Younes, Peter McLaughlin, Barbara Pro, Frederick BHagemeister, Luis Fayad, Jorge Romaguera. Activity of Oxaliplatin in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma. Blood 100:4722, 2002.
128. Younes A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. Addition of Rituximab to Taxol plus Topotecan (TTR) improves response rate and complete remission rate in patients with relapsed/refractory aggressive B-cell lymphoma. Annals of Oncol 13(Suppl 2):246, 2002.
129. Anas Younes, Barbara Pro, Frederick BHagemeister, Maria ARodriguez, Peter McLaughlin, Peter McLaughlin, Luis Fayad, Andre Goy, Fernando Cabanillas. Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil count Recovery after Paclitaxel Plus Topotecan Chemotherapy in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma. Blood 100:2868, 2002.
130. FBHagemeister, Peter McLaughlin, Marilyn Clemons, Maria Alma Rodriguez, Luis Fayad, Jorge Romaguera, Barbara Pro, Andre Goy, Felipe Samaniego, Nam HDang, Fernando Cabanillas. FND (Fludarabine, Mitoxantrone, Dexamethasone)- R(Rituximab) for Patients (pt) with Relapsed (Rel) or Chemotherapy Resistant (CTR) Indolent Lymphomas (IL): A Preliminary Report. Blood 100:4760, 2002.
131. Khouri IF, Saliba R, Hosing C, Kôrbling M, Younes A, Romaguera J, Fayad L, Cabanillas F, Champlin RE. Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma. Annals of Oncol 13(Suppl 2):262, 2002.
132. Romaguera JCabanillas F, Dang N, Goy A, Fayad LE, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros LJ, Gagneja HK. Mantle Cell Lymphoma (MCL). Update on results after R-HCVAD without stem cell transplant (SCT). Annals of Oncol 13(Suppl 2):024, 2002.
133. Barbara Pro, Jorge Romaguera, Homer AMacapinlac, Luis Fayad, Nam HDang, Felipe Samaniego, Andre Goy, Maria ARodriguez, Peter McLaughlin, Donald aPodoloff, Fredrick Hagemeister, Anas Younes, Fernando Cabanillas. Positron Emission Tomography Using Fluorodeoxyglucose but Not Gallium-67 Scintigraphy Is a Sensative Imaging Modality in the Staging of Mantle Cell Lymphoma. Blood 100:3041, 2002.
134. Anas Younes, Luis Fayad, Peter McLaughlin, Andre HGoy, Jorge Romaguera, Maria ARodriguez, Frederick BHagemeister, Felipe Samaniego, Barbara Pro, LJeffrey Medeiros, Chul Ha, Richard Wilder, Alexandra Seifert. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease. Blood 100:4774, 2002.
135. Anas Younes, Luis Fayad, Barbara Pro, Jorge Romaguera, Chul SHa, Richard Wilder. Safety and Efficacy of Prophylactic Pegfilgrastim in Patients with Hodgkin Disease Receiving ABVD Chemotherapy. Blood 100:4179, 2002.
136. Fayad L, Romaguera J, Pro B, Younes A, Dang N, Samaniego F, Garcia P, Sarris A, Rodriguez MA, Hagemeister F, McLaughlin P, Goy A, Cabanillas F, P Rodriguez. Primary Mediastinal Large B-Cell lymphoma (PMLBL): Poor prognosis in patients with extranodal sites. Blood 98(11):Part I of II (#1419), 11/2001.
137. Fayad L, Estey E, Thomas D, O’Brien S, Keating M, Koller C, Pierce S, Talpaz S, Boyer K, Freireich E, Kantarjian H, Kurzrock R. Treatment of Hairy Cell Leukemia with Cladribine (2CDA): Long-term follow-up at M.D. Anderson Cancer Center. Blood 98(11) (#2659), 11/2001.

Last updated: 9/18/2009